The Next GLP-1 Investment Cycle: Structural Transition from Distribution to Infrastructure to Sustainable Health Outcomes
The Next GLP-1 Investment Cycle: Structural Transition from Distribution to Infrastructure to Sustainable Health Outcomes Executive Summary The initial expansion of the glucagon-like peptide-1 (GLP-1). . .
The Next GLP-1 Investment Cycle: Structural Transition from Distribution to Infrastructure to Sustainable Health OutcomesExecutive SummaryThe initial expansion of the glucagon-like peptide-1 (GLP-1) receptor agonist and dual incretin market was defined by a direct-to-consumer distribution race. Early digital health platforms, telehealth prescribers and compounding pharmacies capitalised on immediate consumer demand, focusing heavily on patient acquisition, friction free prescribing and medication fulfilment. However, as the market matures, the fundamental bottleneck has shifted from initial access to long term clinical persistence, metabolic quality preservation, and financial sustainability for risk-bearing entities. Real world evidence demonstrates a stark gap between the clinical efficacy reported in randomised controlled trials and real-world long-term patient retention. While phase 3 clinical trials reported adherence rates exceeding 85% to 95%, real-world claims analyses reveal that 12 month patient persistence historically hovered around 32% to 33%, dropping to 15% at two years and just 8% at three years for individuals utilising GLP-1s for obesity without type 2 diabetes. Although resolving drug shortages improved 12 month persistence to 63% for new initiators in early 2024, multi-year drop-offs remain a significant hurdle. When patients prematurely discontinue therapy, they routinely regain up to two-thirds of their lost weight, neutralising cardio-metabolic improvements and converting high-cost pharmaceutical expenditure into stranded capital for health plans and self-insured employers. Consequently, value creation in digital health and metabolic care has moved away from basic telehealth prescribing toward durable enterprise infrastructure. Capital is flowing into platform solutions capable of proving that patients remain on therapy at month twelve, preserve lean muscle mass, manage gastrointestinal side effects, and generate measurable total cost of care reductions. This report analyses the real world persistence crisis, economic paradoxes confronting payers, core pillars of metabolic care infrastructure, and the emerging investment thesis defining the second phase of the GLP-1 market cycle. The Persistence Breakdown: Real World Attrition versus Clinical Trial ExpectationsA primary challenge facing commercial payers and self-insured employers is the variance between clinical trial persistence and real-world medication retention. In pivotal clinical trials such as STEP and SURMOUNT, controlled protocol enforcement, frequent clinical touchpoints, and fully subsidized medication costs yielded protocol completion rates near 90%. In contrast, broad population claims analyses depict severe long term drop-off across commercial cohorts. Comprehensive longitudinal claims research tracking commercially insured cohorts without diabetes reveals that non-persistence begins early in the treatment journey. Upward of 40% of initial demand is rejected at the pharmacy counter due to coverage restrictions, prior authorisation requirements and step-therapy edits. Among prescriptions approved by payers, an additional 21% of demand is lost to patient abandonment prior to the first fill. For patients who successfully initiate therapy, cumulative attrition steadily escalates over a 36 month horizon, resulting in 90% of total initial potential demand going unrealised by the end of year one. Metric or Cohort HorizonClinical Trial ExpectationsReal-World Claims Data (Obesity without T2D)Key Drivers of Disparity12-Month Persistence85. 0% – 95. 0%32. 3% – 33. 0% (2021 cohort)63. 0% (Q1 2024 cohort)Gastrointestinal intolerance, out-of-pocket costs, prior authorization renewal friction, supply shortages. 24-Month Persistence~80. 0% (Trial extensions)15. 0% overall(Wegovy: 24. 0%, Ozempic: 22. 0%)High cumulative copays, coverage loss, plateaued weight loss, waning motivation. 36-Month PersistenceN/A8. 0% overall (1 in 12)14. 0% for high-potency GLP-1sLong-term financial fatigue, product switching (38%), lack of integrated lifestyle support. Product Switch RateMinimal ( European HealthTech, MedTech, Digital Health Investment BankingNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www. nelsonadvisors. co. ukNelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions. https://www. healthcare. digitalNelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today!https://lnkd. in/e5hTp_xbNelson Advisors LLPHale House, 76-78 Portland Place, Marylebone, London, W1B 1NTMeet Nelson Advisors @ 2026 EventsDigital Health Rewired>March 2026 > Birmingham, UKNHS ConfedExpo>June 2026 > Manchester, UKHLTH Europe>June 2026, Amsterdam, NetherlandsHIMSS AI in Healthcare>July 2026, New York, USABits & Pretzels>September 2026, Munich, GermanyWorld Health Summit 2026>October 2026, Berlin, GermanyHealthInvestor Healthcare Summit>October 2026, London, UKHLTH USA 2026>October 2026, USABarclays Health Elevate>October 2026, London, UKWeb Summit 2026>November 2026, Lisbon, PortugalMEDICA 2026>November 2026, Düsseldorf, GermanyVenture Capital World Summit>December 2026 Toronto, CanadaNelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www. nelsonadvisors. co. uk